期刊簡介 | |||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | MedComm (According to the latest JCR data, this journal is not indexed in the JCR.) LetPub Score 8.2
50 ratings
Rate
Reputation 8.0 Influence 8.3 Speed 7.7 | ||||||||||||||||||||||||||||||||||||||||
期刊簡稱 | |||||||||||||||||||||||||||||||||||||||||
ISSN | 2688-2663 | ||||||||||||||||||||||||||||||||||||||||
h-index | N.A. | ||||||||||||||||||||||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||||||||||||||||||||||
自引率 (2023-2024) | 3.70%自引率趨勢 | ||||||||||||||||||||||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||||||||||||||||||||||
官方網站 | https://onlinelibrary.wiley.com/journal/26882663 | ||||||||||||||||||||||||||||||||||||||||
在線稿件提交 | https://mc.manuscriptcentral.com/medcomm | ||||||||||||||||||||||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||||||||||||||||||||||
出版商 | Wiley | ||||||||||||||||||||||||||||||||||||||||
主題領域 | MEDICINE, RESEARCH & EXPERIMENTAL | ||||||||||||||||||||||||||||||||||||||||
出版國/地區 | Australia | ||||||||||||||||||||||||||||||||||||||||
發行頻率 | 四半期刊行 | ||||||||||||||||||||||||||||||||||||||||
創刊年 | 2020 | ||||||||||||||||||||||||||||||||||||||||
每年文章數 | 201每年文章數趨勢 | ||||||||||||||||||||||||||||||||||||||||
黃金OA百分比 | 81.39% | ||||||||||||||||||||||||||||||||||||||||
OA Related Info | APC: Yes( USD3500; GBP2550; EUR3050; ) APC waiver:Check Notes Other charges: No Keywords: biomedicine、clinical medicine、disease treatment、drug discovery、pathogenesis Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||||||||||||||||||||||
索引 (SCI or SCIE) | |||||||||||||||||||||||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2688-2663%5BISSN%5D | ||||||||||||||||||||||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 10 Weeks | ||||||||||||||||||||||||||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||||||||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[MedComm] 的評論 | 撰寫評論 |
作者: gefche 領域: 生物学 審稿時間: 3.0 month(s) 結果: 修改後接受 撰寫評論 |
2024-03-31 04:58:52 評論於 A very promising new journal, the next big thing for sure, with many spin-off series as well. However, the current pace is incredibly slow, almost unsustainable for the average person(0) 讚! | gefche |
作者: 扎根科研 領域: 医学 審稿時間: 4.0 month(s) 結果: 修改後接受 撰寫評論 |
2023-10-13 12:07:23 評論於 The external audit requirements are quite high. The first major revision had four reviewers, two major revisions, and two minor revisions. The reviewers all felt responsible and raised a lot of questions, nearly 40+. The second minor revision had two reviewers (probably the ones who reviewed the two major revisions before), who still raised many questions and requested the minor revision. The third minor revision was sent to one of the reviewers again, and the editor-in-chief also made some suggestions. The fourth time, it was finally accepted (pre-accepted only), but a careful check and revision of the final version still need to be submitted. Then it's signing the copyright agreement, paying the page fee, proofreading before publication... Although it is a new journal, the initial IF is close to 10, destined to be a 10+ or even 20+ magazine in the future. Checking, I found that this journal is a sister publication of Signal Transduction and Targeted Therapy, with the same editor-in-chief. It will also follow the development model of STTT in the future, with unlimited potential. Overall, the quality of this journal is quite high at the moment, and its future development potential should be good too. It is also because of these reasons that some big names are submitting papers...I was also introduced by a classmate from a big-shot's research group to try it out first, haha(1) 讚! | 扎根科研 |
作者: 扎根科研 領域: 医学 審稿時間: 4.0 month(s) 結果: 修改後接受 撰寫評論 |
2023-10-13 12:03:42 評論於 Here, I briefly share my submission process: Submitted on April 7th, undergoing initial checking; Around April 15th, sent for external review, under review status; May 20th, initial review completed, received Major revision decision; June 11th, revised, undergoing initial checking status; June 27th, second review completed, received Minor revision decision; July 8th, revised, undergoing initial checking status; July 21st, third review completed, received another Minor revision decision; July 25th, revised, undergoing initial checking status; July 30th, finally received Acceptance email, but it's only provisional, still need to revise and submit final version; August 5th, received acceptance for final version email(208) 讚! | 扎根科研 |
作者: Levy 領域: 生物学 審稿時間: 2.0 month(s) 結果: 修改後接受 撰寫評論 |
2022-04-07 23:48:44 評論於 No impact factor, low cost-effectiveness.(5) 讚! | Levy |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us